Centogene N.V. (Nasdaq: CNTG), the essential life science partner
for data-driven answers in rare and neurodegenerative diseases,
today announced that it has been recognized by the French Ministry
of Higher Education and Research as a qualified organization to
support partners conducting R&D projects in France.
Accordingly, it has received accreditation under the French R&D
tax credit initiative ('Crédit d'Impôt Recherche', CIR) for a
three-year period.
The CIR initiative enables eligible research-based companies,
who are subject to corporate tax in France, to claim tax relief on
30% of all costs (up to €100 million) incurred in R&D
activities outsourced to CENTOGENE.
Prof. Peter Bauer, Chief Medical & Genomic Officer at
CENTOGENE, stated, “'We are excited to receive this accreditation
as it recognizes our advanced research capabilities that we support
our customers with. By lowering overall R&D costs, we will be
able to support our current and future partners in generating novel
insights and delivering data-driven, life-changing answers to rare
and neurodegenerative disease patients.”
To learn more about the CIR initiative, visit:
https://link.centogene.com/cir
About CENTOGENE
CENTOGENE’s mission is to provide data-driven, life-changing
answers to patients, physicians, and pharma companies for rare and
neurodegenerative diseases. We integrate multiomic technologies
with the CENTOGENE Biodatabank – providing dimensional analysis to
guide the next generation of precision medicine. Our unique
approach enables rapid and reliable diagnosis for patients,
supports a more precise physician understanding of disease states,
and accelerates and de-risks targeted pharma drug discovery,
development, and commercialization.
Since our founding in 2006, CENTOGENE has been offering rapid
and reliable diagnosis – building a network of approximately 30,000
active physicians. Our ISO, CAP, and CLIA certified multiomic
reference laboratories in Germany utilize Phenomic, Genomic,
Transcriptomic, Epigenomic, Proteomic, and Metabolomic datasets.
This data is captured in our CENTOGENE Biodatabank, with over
800,000 patients represented from over 120 highly diverse
countries, over 70% of whom are of non-European descent. To date,
the CENTOGENE Biodatabank has contributed to generating novel
insights for more than 285 peer-reviewed publications.
By translating our data and expertise into tangible insights, we
have supported over 50 collaborations with pharma partners.
Together, we accelerate and de-risk drug discovery, development,
and commercialization in target and drug screening, clinical
development, market access and expansion, as well as offering
CENTOGENE Biodata Licenses and Insight Reports to enable a world
healed of all rare and neurodegenerative diseases.
To discover more about our products, pipeline, and
patient-driven purpose, visit www.centogene.com and follow us on
LinkedIn.
Forward-Looking Statements
This press release contains “forward-looking statements” within
the meaning of the U.S. federal securities laws. Statements
contained herein that are not clearly historical in nature are
forward-looking, and the words “anticipate,” “believe,”
“continues,” “expect,” “estimate,” “intend,” “project,” “plan,” “is
designed to,” “is set to,” “potential,” “predict,” “objective” and
similar expressions and future or conditional verbs such as “will,”
“would,” “should,” “could,” “might,” “can,” and “may,” or the
negative of these are generally intended to identify
forward-looking statements. Such forward-looking statements involve
known and unknown risks, uncertainties, and other important factors
that may cause CENTOGENE’s actual results, performance, or
achievements to be materially different from any future results,
performance, or achievements expressed or implied by the forward-
looking statements. Such risks and uncertainties include, among
others, negative economic and geopolitical conditions and
instability and volatility in the worldwide financial markets,
possible changes in current and proposed legislation, regulations
and governmental policies, pressures from increasing competition
and consolidation in our industry, the expense and uncertainty of
regulatory approval, including from the U.S. Food and Drug
Administration, changes in our mix of customers and partners and
their order practices with respect to our products and solutions,
our reliance on third parties and collaboration partners, including
our ability to manage growth, execute our business strategy and
enter into new client relationships, our dependency on the rare
disease industry, our ability to manage international expansion,
our reliance on key personnel, our reliance on intellectual
property protection, fluctuations of our operating results due to
the effect of exchange rates, our ability to streamline cash usage,
our continued ongoing compliance with covenants linked to financial
instruments, our requirement for additional financing, and our
ability to continue as a going concern, or other factors. For
further information on the risks and uncertainties that could cause
actual results to differ from those expressed in these
forward-looking statements, as well as risks relating to
CENTOGENE’s business in general, see CENTOGENE’s risk factors set
forth in CENTOGENE’s Form 20-F filed on May 16, 2023, with the
Securities and Exchange Commission (the “SEC”) and subsequent
filings with the SEC. Any forward-looking statements contained in
this press release speak only as of the date hereof, and CENTOGENE
specifically disclaims any obligation to update any forward-looking
statement, whether as a result of new information, future events,
or otherwise.
CONTACT
CENTOGENE
Melissa HallCorporate Communications Press@centogene.com
Lennart StreibelInvestor Relations IR@centogene.com
Centogene NV (NASDAQ:CNTG)
Historical Stock Chart
Von Aug 2024 bis Sep 2024
Centogene NV (NASDAQ:CNTG)
Historical Stock Chart
Von Sep 2023 bis Sep 2024